Author: Maureen Heydt

Green Financial Regulatory Policy for Latin America in the Aftermath of COVID-19

For over a year now, the COVID-19 pandemic has strained governments, economies and public health to within breaking point. In South America alone, there have been over 25 million recorded cases of COVID-19 and 679,376 deaths, with an outbreak in Brazil that is the third largest in the world. Amid this great human and economic […]

Green Transformation in China: Structures of Endowment, Investment and Employment

By Yan Wang China’s economic growth and development over the past 40 years has been remarkable, lifting over 700 million people out of poverty. However, this growth has come with huge costs to the environment and a resultant loss in productivity. According to the World Bank Group, if China could shift to a greener growth […]

Why is the International Monetary System Hierarchical?

By Steffen Murau, Fabian Pape and Tobias Pforr The view that the international monetary system is hierarchical has become increasingly common in International Political Economy (IPE) scholarship. Yet the nature, shape, and origin of this hierarchy often remain vague, as assessments vary considerably based on the analytical starting point. For example, is it a hierarchy […]

Trade and Access to Medicines in the COVID-19 Era: GDP Center Roundup

By Rachel Thrasher The COVID-19 pandemic has brought the existing challenges of equitable access to affordable medicines into sharp relief. With almost 3 million deaths globally, every country in the world is dealing with an unprecedented disease burden on the health care system, the economic impacts of mandated public and private sector shut-downs and increasingly […]

Making International Intellectual Property and Trade Regimes Work to Address the Health Response to COVID-19: The Burdens of Exclusivity

The world was unprepared for COVID-19, despite other recent coronavirus outbreaks and despite multiple warnings from the World Health Organization (WHO) and others. Although there was an initial sharing of research among scientists and an unleashing of significant public, charitable and private funding to develop, test and expand manufacturing capacity of new COVID-19-related medicines, vaccines […]

Evaluating the Impact of Data Exclusivity on the Price per Kilogram of Pharmaceutical Imports

All of the US Free Trade Agreements (FTAs) signed in the past 20 years have required trading partners to enact stronger intellectual property (IP) laws than those stipulated by the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement), provisions commonly referred to as “TRIPS-Plus.” This includes trade agreements made […]